Reducing mortality from 2019-nCoV: host-directed therapies should be an option
Alimuddin Zumla, David S Hui, Esam I Azhar, Ziad A Memish, Markus Maeurer
Published:February 05, 2020DOI:https://doi.org/10.1016/S0140-6736(20)30305-6
The number of confirmed cases of the 2019 novel coronavirus (2019-nCoV) reported to WHO continues to rise worldwide.1 As with two other WHO Blueprint priority coronaviruses, SARS-CoV2 and MERS-CoV,3 2019-nCoV is lethal. As of Feb 3, 2020, 2019-nCoV has caused 362 deaths out of 17?391 confirmed cases reported to WHO.1 No specific anti-viral treatment exists. The mainstay of clinical management is largely symptomatic treatment, with organ support in intensive care for seriously ill patients. The unprecedented flurry of activity by WHO and other global public health bodies has mainly focused on preventing transmission, infection control measures, and screening of travellers. The development of vaccines has received immediate funding; however, as with SARS-CoV and MERS-CoV, support for developing treatments for 2019-nCoV that reduce mortality has not been forthcoming. There is an urgent need for focusing funding and scientific investments into advancing novel therapeutic interventions for coronavirus infections.